Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of subcutaneous TEV-48125 (fremanezumab) for preventive treatment of migraine
2015-004550-18Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fremanezumab in migraine and chronic migraine, sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Occurrence of adverse events. Started May 2016; status: completed.
02
Drugs
fremanezumab
03
Conditions
migrainechronic migraine
Beyond the preview
Go deeper on 2015-004550-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004550-18.